Atopic dermatitis: a review of evolving targeted therapies

Atopic dermatitis (AD) is a chronic inflammatory skin condition, affecting a significant number of patients of all ages. As we learn more about the pathogenesis of AD, new targeted treatment options are being developed to better tailor its management. Currently, a variety of biologic agents are utilized to target specific components and regulators of the inflammatory pathways in allergic and inflammatory conditions. These targeted therapies allow for greater efficacy while limiting adverse effects. Areas covered: This review examines the current literature in respect to several different monoclonal antibodies that are being studied toward a personalized approach in the treatment of AD. Expert opinion: Several trials examining the use of biologics for AD have demonstrated mixed success. While some have shown promise for improvement of clinical symptoms, there are several barriers to support consistent use including cost, adverse effects, small sample sizes, conflicting evidence, and lack of demonstrated long-term safety and efficacy. The ultimate goal for future research is to develop biomarkers for different AD phenotypes in order to allow for targeted therapy of AD.